Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04317963 · ClinicalTrials.gov registry record
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
A clinical trial, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- 180
- Enrollment target
NCT04317963 is a clinical trial that has completed, run by University of Illinois at Chicago. The registered enrollment target is 180 participants.
The verdict
NCT04317963 has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- 180 participants
- Enrollment target
Study Summary
This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical center's specialty outpatient clinic.
Interventions
- BIOLOGICAL Bezlotoxumab
- DRUG Standard CDI treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2020-02-12 |
| Est. Completion | 2023-02-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04317963
The ClinicalTrials.gov registry entry for NCT04317963 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bezlotoxumab is the first listed.
NCT04317963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04317963 about?
NCT04317963 is a clinical study titled "Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection". This is a retrospective case:control study examining the use of adjunctive bezlotoxumab to standard C. difficile infection (CDI) treatment compared to standard CDI treatment alone in patients with CDI seen in an academic medical center's specialty outpatient clinic.
What is the current status of trial NCT04317963?
This trial is currently completed. The enrollment target is 180 participants. The study started on 2020-02-12. Estimated completion is 2023-02-22.
What interventions are being tested in trial NCT04317963?
The interventions under investigation include: Bezlotoxumab (BIOLOGICAL), Standard CDI treatment (DRUG).
Who is sponsoring clinical trial NCT04317963?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.